Casi Pharmaceuticals, INC. 6-K Filing
Ticker: CASIF · Form: 6-K · Filed: Dec 31, 2025 · CIK: 1962738
Sentiment: neutral
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 13.9 · Accepted 2025-12-30 17:49:34
Key Financial Figures
- $20 million — issuance of the first tranche of its US$20 million convertible note financing pursuant to
- $5 million — tible note with a principal amount of US$5 million has been issued to the Purchaser. Such
- $0.0001 — ary shares of the Company, par value US $0.0001 per share (the “Shares”), a
- $2 — the conversion price be higher than US $2 per ordinary Share or lower than US $1
- $1 — $2 per ordinary Share or lower than US $1 per Share. Forward-Looking Statements
Filing Documents
- tm2534488d1_6k.htm (6-K) — 13KB
- 0001104659-25-125300.txt ( ) — 14KB
Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ David Cory Name: David Cory Title: CEO Date: December 30, 2025